Early-Stage Programs

Our HIF-based Portfolio

Akebia Therapeutics is developing a HIF-based portfolio of product candidates that target serious diseases of high unmet need. Our portfolio includes product candidates developed internally, as well as in-licensed product candidates.

AKB-5169

AKB-5169 was licensed from Janssen Pharmaceutica NV along with an extensive library of well-characterized HIF pathway compounds, with potential applications across multiple therapeutic areas.

AKB-5169 is in exploratory development as an oral treatment for inflammatory bowel disease (IBD). We hope to complete further preclinical development in order to file an Investigational New Drug application with the FDA in 2018.

 

AKB-5169 is an investigational drug and has not yet been approved by the US Food and Drug Administration (FDA) or any regulatory authority.